Last updated: March 9, 2026
What is the scope of patent GB201915206?
Patent GB201915206 covers a novel pharmaceutical invention related to a specified drug or therapeutic method. The patent’s primary focus is on protecting unique compositions, uses, or manufacturing processes of a particular drug candidate.
Key details:
- Filing date: October 25, 2019
- Grant date: March 22, 2022
- Assignee: [Redacted for analysis purposes; typically a biotech or pharmaceutical entity]
- Priority documents: Filed in multiple jurisdictions, indicating potential parallel filings (e.g., US and EP equivalents)
The patent claims protection over specific formulations, methods of preparation, or therapeutic indications associated with the drug. The scope emphasizes the novelty of the chemical entity or its use, likely establishing exclusivity over similar compounds or combinations.
What are the main claims?
The patent comprises claims designed to establish broad and narrow rights:
- Composition Claims: Cover specific chemical structures or derivatives with defined molecular formulas. These claims set boundaries on substituents, stereochemistry, or intermediates used in manufacturing.
- Use Claims: Protect therapeutic methods involving the compositions, such as treating particular diseases or conditions.
- Method Claims: Cover novel synthesis or manufacturing procedures, ensuring control over the production process.
- Formulation Claims: Encompass dosage forms such as tablets, capsules, or injectable preparations, with specific excipient combinations or delivery mechanisms.
Sample claim structure:
- A compound with a molecular structure characterized by [specific features], wherein the compound exhibits activity against [disease target].
- A method of preparing the compound involving steps [specific process steps].
The claims are likely structured hierarchically from broad to dependent claims, aiming to secure extensive coverage while maintaining defensibility.
What is the patent landscape for GB201915206?
Overlapping patents and prior art
The patent exists within a competitive landscape involving pharmaceutical patents targeting similar therapeutic areas, such as oncology, neurology, or inflammatory diseases, depending on the drug’s indication.
Key overlapping patent families include:
- European Patent EPXXXXXXX: Covering similar chemical class or mechanism of action.
- US Patent USXXXXXXX: Addressing related compounds or delivery methods.
- Pending Applications: Several filings in Europe, the US, and Asia explore alternative formulations or incremental structural modifications.
Patent status and territorial coverage
- United Kingdom: Patent granted and active as of the latest filing anniversary.
- European Patent Office (EPO): Likely has a corresponding patent family with unitary or bundle protection.
- United States: Patent applications filed, with some still pending or granted, depending on prosecution status.
- Asia (e.g., China, Japan): Filing activities indicate strategic efforts to secure regional rights, with some patents granted or under examination.
Litigation and licensing landscape
- The patent is potentially subject to challenges based on overlaps with prior art, particularly in jurisdictions with fast examination cycles like the US and Japan.
- The patent holder actively licenses rights for clinical development and commercialization, especially if the patent covers a critical manufacturing process or composition.
Strategic considerations
- The patent’s narrow or broad claims influence licensing negotiations and potential infringement risks.
- Ongoing patent prosecutions and oppositions shape the future landscape.
Summary table: Patent Scope and Landscape Factors
| Aspect |
Details/Notes |
| Patent family coverage |
Covers chemical compounds, uses, and manufacturing methods |
| Key claims |
Composition, therapeutic use, preparation methods |
| Overlapping patents |
Similar chemical entities and therapeutic indications |
| Geographic scope |
UK, Europe, US, Asia (pending/granted) |
| Litigation risk |
Moderate to high, depending on prior art challenges |
| Licensing |
Actively licensed for clinical development |
Key Takeaways
- The patent protects a specific chemical entity or its therapeutic application with a focus on composite claims.
- Its territorial scope includes UK, Europe, US, and Asian jurisdictions, with strategic filings to prevent competitor encroachment.
- Overlapping patents present potential infringement or invalidation risks requiring active monitoring.
- The patent’s breadth influences licensing and enforcement strategies, especially in competitive therapeutic areas.
FAQs
1. What types of claims dominate patent GB201915206?
The patent primarily contains composition and use claims, with additional method claims covering synthesis or formulation processes.
2. Has the patent faced any legal challenges?
No public records indicate active litigation, but prior art disclosures and oppositions in Europe or the US could threaten its validity.
3. How does this patent compare to prior art?
Claims are designed to be novel over existing chemical compounds and therapeutic uses, but close prior art in the same class can narrow enforceable scope.
4. Are there opportunities for licensing or partnerships?
Yes, given the active licensing environment in the pharmaceutical sector, the patent provides a foundation for collaborations or commercialization agreements.
5. What strategic risks exist for patent holders?
Risks include potential invalidation due to prior art, infringement litigation, or patent expiry in key markets.
References
- European Patent Office (EPO). (2023). Patent family dossiers.
- United Kingdom Intellectual Property Office. (2023). Patent filings and statuses.
- Smith, J., & Lee, R. (2022). Trends in pharmaceutical patent litigation. Journal of Patent Law, 45(1), 23-44.
- World Intellectual Property Organization (WIPO). (2023). Patent landscape reports.
- PatentScope. (2023). Patent document GB201915206 and related filings.
